Navigating regulatory hurdles in the U.S. and Europe, plus fierce competition from rival Apellis, Astellas’ geographic ...

AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...

Avalere Health has reset both its executive team and mission. | Amar Urhekar has reset Avalere Health’s mission. Weeks after naming Urhekar as CEO, the biopharma commercialization partner has aligned ...

Novo expects to continue to grow its reach in 2025, though perhaps not at the magnitude witnessed in 2024. For the full year to come, Novo Nordisk is eyeing sales growth at constant currencies between ...

After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

As Moderna maps out a more cautious future amid lower-than-expected sales of its current products, the company is bolstering ...

The CDC Foundation has added muscle to its “Live to the Beat” campaign, enlisting former NFL star Jerome “The Bus” Bettis to ...

Three strikes and you’re out? Not for Supernus Pharmaceuticals and its Parkinson’s disease infusion pump. | The device is ...

Seven months after the FDA signed off on a reintroduction of Roche’s eye implant Susvimo, the U.S. regulator has broadened ...

With one foot already in the healthcare realm, multi-industry manufacturer Jabil is beefing up its biopharma bona fides with ...

As the major cost-cutting initiative at Bristol Myers Squibb rolls on, the company has launched another round of layoffs in ...